Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Microfluidic device captures, allows analysis of tumor-specific extracellular vesicles

28.02.2018

Potential biomarkers could help monitor treatment response, guide clinical decisions

A new microfluidic device developed by investigators at Massachusetts General Hospital (MGH) may help realize the potential of tumor-derived extracellular vesicles (EVs) - tiny lipid particles that carry molecules through the bloodstream - as biomarkers that could monitor a tumor's response to therapy and provide detailed information to guide treatment choice.


Schematic image showing how the antibody-coated surfaces of the EVHB-Chip capture red- and green-labeled tumor-specific extracellular vesicles from patient serum or plasma.

Credit: Eduardo Reátegui, PhD, Center for Engineering in Medicine, Massachusetts General Hospital

Usage restricted to coverage of the paper described in this release.

In their report published earlier this year in Nature Communications, the team from the MGH Center for Engineering in Medicine (MGH-CEM) describes how EVs captured from serum or plasma samples of patients with the dangerous brain tumor glioblastoma multiforme (GBM) provided detailed, tumor-specific genetic and molecular information.

"Glioblastoma is a highly fatal disease with few treatment options," says senior author Shannon Stott, PhD, of the MGH Cancer Center and the BioMEMS Resource Center in the MGH-CEM. "Due to the tumor's location, it has been challenging to get dynamic, real-time molecular information, which limits the ability to determine tumor progression and to match patients with the most promising new therapies. Our device's ability to sort tumor-specific EVs out from the billions of EVs carried through the bloodstream may lead to the development of much-needed diagnostic and monitoring tools for this and other hard-to-treat cancers."

Previous technologies designed to isolate EVs were limited in their ability to distinguish tumor EVs from those carrying molecules from non-malignant cells. More specific approaches using tumor-specific antibodies were time-consuming and cumbersome or did not capture sufficient numbers of tumor-specific EVs from a sample.

Other "liquid biopsy" technologies designed to capture tumor cells and molecules - such as several circulating tumor cell (CTC)-isolating devices developed by member of the MGH team - may be limited in their ability to monitor brain tumors throughout treatment. Since these potential biomarkers may not consistently pass through the blood brain barrier, their presence at the time a blood sample is drawn may be limited.

Stott's team combined features of the CTC-detecting HB-Chip, which she helped to develop, with features specific to the capture of EVs. The surfaces through which a sample is passed are optimized to the physical properties of EVs - which are thousands of times smaller than cells - and contain a "cocktail" of antibodies against proteins highly expressed on GBM cells. The team also identified factors that increased the number of tumor-specific EVs captured from a sample and developed methods for releasing EVs from the device while preserving their contents for detailed analysis. Taking this approach, their device can isolate as few as 100 nanometer-sized vesicles in a one-microliter droplet of plasma.

Using the new device, dubbed the EVHB-Chip, the researchers analyzed serum or plasma samples from 13 patients with GBM and 6 control samples from healthy donors. The EVHB-Chip isolated tumor-specific EVs from all 13 patients, and identified the EGFRvIII mutation in 5 of 6 patients tested for that mutation. The captured EVs also identified genes present in the four characteristic subtypes of GBM and revealed the upregulation of more than 50 cancer-associated genes, some not previously observed in GBM EVs.

An assistant professor of Medicine at Harvard Medical School, Stott notes that the great specificity and sensitivity of the EVHB-Chip allow the use of relatively small blood samples, which would be particularly beneficial for pediatric patients for whom other blood biopsy approaches are not always feasible. The flexibility of the device should allow it to be useful for many types of cancer and, since all cells release EVs into the circulation, for other conditions including infectious diseases, autoimmune diseases, cardiac events and neurodegenerative disorders. Simultaneous investigations of biomarkers provided by EVs, CTCs and circulating DNA should help determine which can be most informative for specific patients and stages of treatment.

Stott notes that the EVHB-Chip was designed to be a low-cost, easy to use device with the hope of rapid translation to the clinic. "We are excited by this early-stage data, and we look forward to scaling the technology and increasing the number of patient samples analyzed. Specifically, we are interested in exploring how these vesicles change over time in response to treatment, and we see our blood-based assay as an ideal way to explore this in brain tumor patients," she says.

###

The co-lead authors of the Nature Communications report are Eduardo Reátegui, PhD, of the MGH-CEM and Kristan van der Vos, PhD, and Charles Lai, PhD, MGH Neurodiscovery Center. Additional co-authors are Mahnaz Zeinali, Berent Aldikacti, Frederick Floyd Jr, Aimal Khankhel, and Mehmet Toner, PhD; MGH-CEM; Nadia Atai, PhD, Leonora Balaj, PhD, and Xandra Breakefield, PhD, MGH Neurodiscovery Center; Brian V. Nahed, MD, and Bob Carter, MD, PhD, MGH Neurosurgery and MGH Cancer Center; Vishal Thapar, Lecia Sequist, MD, and David Ting, MD, MGH Cancer Center; and Fred Hochberg, University of California at San Diego. The study was supported by National Institutes of Health grants CA069246, U19 CA179563, EB008047 and P41 EB002503-11 and grants from Voices Against Brain Cancer, the Wang Pediatric Brain Tumor Collaborative and the Canadian Institute of Health Research. The MGH has filed a patent application for the work described in this paper.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $900 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."

Media Contact

Katie Marquedant
kmarquedant@partners.org
617-726-0337

 @MassGeneralNews

http://www.mgh.harvard.edu 

Katie Marquedant | EurekAlert!

Further reports about: Biomarkers CANCER blood brain tumor extracellular vesicles vesicles

More articles from Health and Medicine:

nachricht Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering

nachricht New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data storage using individual molecules

Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.

Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Pressure tuned magnetism paves the way for novel electronic devices

18.12.2018 | Materials Sciences

New type of low-energy nanolaser that shines in all directions

18.12.2018 | Physics and Astronomy

NASA research reveals Saturn is losing its rings at 'worst-case-scenario' rate

18.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>